Last Update 23 Oct 25
Fair value Decreased 1.03%Analysts Lower Clorox Price Target Amid Service Disruptions and Muted Profit Outlook
Clorox's analyst price target was reduced from approximately $131.24 to $129.88, as analysts cite ongoing service disruptions, slowing sales growth, and a muted profit outlook as key factors for the adjustment.
Analyst Commentary
Recent research updates indicate that analysts remain cautious on Clorox shares, reflecting ongoing challenges and a muted growth outlook. Several price target reductions highlight concerns about company execution and the current profitability environment.
Bullish Takeaways
- Bullish analysts note that Clorox continues to maintain a stable position within the consumer staples sector. This stability may offer some resilience amid broader market volatility.
- While recent price target reductions have occurred, the decision to maintain Hold or Neutral ratings indicates some confidence in Clorox's long-term fundamentals and the potential for improvement when operational disruptions are resolved.
- Ongoing efforts to address service disruptions and transition challenges are viewed as necessary steps that could support future margin stability and stronger execution.
Bearish Takeaways
- Bearish analysts are adjusting expectations for both topline growth and earnings per share, reacting to headwinds from slower sales and the lingering impacts of service disruptions.
- Concerns persist regarding operating deleverage and subdued organic sales, particularly as weak retail tracking data points to continued softness in core business units.
- Muted and decelerating growth trends in certain segments, such as personal care, continue to affect the near-term valuation and limit potential upside for shares.
- Model adjustments throughout the sector indicate a broader trend of caution and reinforce a lack of immediate catalysts for significant growth acceleration at Clorox.
What's in the News
- CloroxPro launched Clorox Screen+ Sanitizing Wipes, specifically designed for cleaning and sanitizing sensitive electronics. The wipes provide a bleach-free solution that kills 99.9% of bacteria and helps prolong device longevity (Key Developments).
- Between April 1 and June 30, 2025, Clorox repurchased 565,378 shares for $75 million, completing the buyback of over 8 million shares valued at more than $1.27 billion since 2018 (Key Developments).
- Clorox issued guidance for fiscal year 2026, anticipating net sales to decrease by 6% to 10% year over year. Organic sales are expected to be down 5% to 9% and diluted EPS is projected to range from $5.60 to $5.95, reflecting ongoing headwinds from prior ERP transition impacts (Key Developments).
- The company increased its quarterly dividend from $1.22 to $1.24 per share, payable August 29, 2025, to shareholders of record as of August 13, 2025 (Key Developments).
Valuation Changes
- Fair Value: Decreased slightly from $131.24 to $129.88, reflecting modestly lower expectations for company valuation.
- Discount Rate: Remained unchanged at 6.78%, indicating consistent risk assumptions in current valuation models.
- Revenue Growth: Declined from -0.44% to -0.49%, pointing to marginally weaker expected revenue performance.
- Net Profit Margin: Dropped from 12.58% to 11.97%, suggesting pressure on profitability projections.
- Future P/E: Increased from 21.20x to 22.08x. This indicates a slightly higher forward valuation relative to expected earnings.
Key Takeaways
- Modern ERP implementation and digital transformation efforts are expected to improve supply chain efficiencies, reduce costs, and drive sustained margin and earnings growth.
- Product innovation and premium offerings in health, wellness, and cleaning are set to regain market share and fuel organic, long-term revenue growth.
- Intensifying competition, cost pressures, and shifting consumer trends threaten Clorox's margins, revenue growth, and ability to sustain its premium brand and pricing advantages.
Catalysts
About Clorox- Engages in the manufacture and marketing of consumer and professional products worldwide.
- The full-scale implementation of a modern ERP system is expected to drive long-term operational efficiencies – improving supply chain visibility, speeding innovation cycles, and reducing structural costs – which should support margin expansion and sustained earnings growth once short-term transition noise normalizes.
- Acceleration of product innovation and the launch of new platforms in the back half of fiscal 2026 aligns with consumers' heightened demand for superior and differentiated experiences in household, health, and cleaning products, positioning Clorox to regain market share and drive organic revenue growth.
- Increased investment and capability in digital marketing and data analytics, coupled with rising e-commerce penetration, will allow Clorox to engage consumers more directly, optimize pricing and promotional strategies, and improve channel mix, boosting both top line growth and net margin improvement.
- Ongoing cost optimization initiatives, including holistic margin management and productivity enhancements enabled by digital transformation, are expected to offset inflationary headwinds and tariffs, stabilizing or expanding gross and EBIT margins over time.
- Clorox's expanded focus on differentiated and premium innovations (such as green cleaning solutions and wellness-oriented products) is positioned to capitalize on the global health, hygiene, and wellness focus post-pandemic-supporting premiumization, lifting average selling prices, and supporting long-term revenue and earnings growth.
Clorox Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?- Analysts are assuming Clorox's revenue will decrease by 0.4% annually over the next 3 years.
- Analysts assume that profit margins will increase from 11.4% today to 12.6% in 3 years time.
- Analysts expect earnings to reach $881.8 million (and earnings per share of $7.13) by about September 2028, up from $810.0 million today. The analysts are largely in agreement about this estimate.
- In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 21.6x on those 2028 earnings, up from 19.0x today. This future PE is about the same as the current PE for the US Household Products industry at 21.6x.
- Analysts expect the number of shares outstanding to decline by 1.19% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.
Clorox Future Earnings Per Share Growth
Risks
What could happen that would invalidate this narrative?- Clorox is experiencing sluggish category growth and faces continued uncertainty around consumer demand, with management acknowledging that expectations for category normalization and sustainable top-line improvements remain unclear, which could negatively impact revenue growth in the coming years.
- The company is dealing with heightened price competition and deep discounting in key segments like Glad and Cat Litter, as well as increased promotional intensity from private label and competitors; this could compress net margins and reduce overall earnings as Clorox is forced to defend its market share.
- Clorox is highly reliant on a few core premium brands for revenue, and when product superiority falters or execution issues arise (especially post-cyberattack in Cat Litter and Kingsford), it can disproportionately impact top-line performance and limit the effectiveness of strategic innovation.
- Rising input costs, persistent inflation, tariffs, and continued supply chain pressure pose ongoing threats to gross margins; while management anticipates offsetting these with productivity and ERP benefits, they acknowledge significant uncertainty and volatility in both costs and their ability to fully offset these headwinds.
- Secular consumer trends-such as increasing value-seeking behavior, channel shifting to e-commerce, and a gradual uptick in private label and "natural" alternatives in some categories-could erode Clorox's pricing power and brand advantage, resulting in pressured revenues and challenged earnings growth over the long term.
Valuation
How have all the factors above been brought together to estimate a fair value?- The analysts have a consensus price target of $133.588 for Clorox based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $166.0, and the most bearish reporting a price target of just $115.0.
- In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $7.0 billion, earnings will come to $881.8 million, and it would be trading on a PE ratio of 21.6x, assuming you use a discount rate of 6.8%.
- Given the current share price of $125.68, the analyst price target of $133.59 is 5.9% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
How well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.



